Acute and Longer-Term Effects of COVID-19 on Auditory and Vestibular Symptoms.

Autor:	Berlot AA; Albert Einstein College of Medicine, the Bronx, New York., Moskowitz HS; Albert Einstein College of Medicine, the Bronx, New York., Lin J; Albert Einstein College of Medicine, the Bronx, New York., Liu J; Albert Einstein College of Medicine, the Bronx, New York., Sehanobish E; Albert Einstein College of Medicine, the Bronx, New York., Jerschow E; Allergy Division Chair, Mayo Clinic, Rochester, Minnesota., Ow TJ; Albert Einstein College of Medicine, the Bronx, New York., Sussman ES; Albert Einstein College of Medicine, the Bronx, New York.
Jazyk:	angličtina
Zdroj:	Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology [Otol Neurotol] 2023 Dec 01; Vol. 44 (10), pp. 1100-1105. Date of Electronic Publication: 2023 Sep 29.
DOI:	10.1097/MAO.0000000000004027
Abstrakt:	Objective: To evaluate long-term effects of COVID-19 on auditory and vestibular symptoms in a diverse cohort impacted by the initial 2020 COVID-19 infection in the pandemic's epicenter, before vaccine availability. Study Design: Cohort study of individuals with confirmed COVID-19 infection, diagnosed in the March-May 2020 infection wave. A randomized, retrospective chart review of 1,352 individuals was performed to identify those with documented new or worsening auditory (aural fullness, tinnitus, hyperacusis, hearing loss) or vestibular (dizziness, vertigo) symptoms. Those with documented symptoms (613 of the 1,352 initial cohort) were contacted for a follow-up telephone survey in 2021-2022 to obtain self-report of aforementioned symptoms. Setting: Academic tertiary hospital system in Bronx, NY. Patients: Adults 18 to 99 years old with confirmed COVID-19 infection, alive at time of review. One hundred forty-eight charts were excluded for restricted access, incomplete data, no COVID-19 swab, or deceased at time of review. Intervention: Confirmed COVID-19 infection, March to May 2020. Main Outcomes Measures: Auditory and vestibular symptoms documented in 2020 medical records and by self-report on 2021 to 2022 survey. Results: Among the 74 individuals with documented symptoms during the first 2020 COVID-19 wave who participated in the 2021 to 2022 follow-up survey, 58% had documented vestibular symptoms initially in 2020, whereas 43% reported vestibular symptoms on the 2021 to 2022 survey ( p = 0.10). In contrast, 9% had documented auditory symptoms initially in 2020 and 55% reported auditory symptoms on the 2021 to 2022 survey ( p < 0.01). Conclusions: COVID-19 may impact vestibular symptoms early and persistently, whereas auditory effects may have more pronounced long-term impact, suggesting the importance of continually assessing COVID-19 patients. Competing Interests: Conflict of interest disclosures: Dr. Jershow is part of an advisory board for GlaxoSmithKline and Regeneron/Sanofi. Dr. Jerschow is also a consultant for GlaxoSmithKline and receives research funding from the National Institutes of Health (NIH), AstraZeneca, and Regeneron. Dr. Ow discloses relationships with Takeda (Millennium Pharmaceuticals, Inc.), Bristol Myers Squibb, and Presage Biosciences, Inc. Dr. Ow is the site Principal Investigator for a phase 0 study supported by Presage Biosciences, Inc., with substudies sponsored by Takeda (Millenium Pharmaceuticals, Inc.) and Bristol Myers Squibb. All other authors have no conflicts of interest to disclose. (Copyright © 2023, Otology & Neurotology, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu